Next year, submit a new indication application for the blockbuster IL-4/IL-13 inhibitor phase 3 clinical report again

Today, Regeneron and Sanofi announced that Dupixent, a blockbuster IL-4/IL-13 inhibitor, reached the dual primary endpoint in the second clinical trial for the treatment of eosinophilic esophagitis (EoE)

Eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease that damages the esophagus and causes it to not work properly

Dupixent is a fully humanized monoclonal antibody that can inhibit the signal transduction of interleukin 4 (IL-4) and interleukin 13 (IL-13) proteins

▲The mechanism of Dupixent (picture source: Sanofi official website)

The results of this phase 3 clinical trial showed that after 24 weeks of treatment:

Symptoms of the disease in the Dupixent group were reduced by 64% compared to baseline compared to 41% in the placebo group (p=0.

59% of patients in the Dupixent group achieved histological disease remission, which was nearly 10 times that of the placebo group (6%) (p<0.

In terms of safety, the results of this clinical trial are consistent with the safety characteristics of Dupixent in the approved indications

Reference materials:

[1] SECOND DUPIXENT® (DUPILUMAB) PHASE 3 EOSINOPHILIC ESOPHAGITIS TRIAL TO DEMONSTRATE SIGNIFICANT DISEASE IMPROVEMENTS, UNDERSCORING ROLE OF TYPE 2 INFLAMMATION IN THIS COMPLEX DISEASE.